Development and Evaluation of Lactose-Free Single-Unit and Multiple-Unit Preparations of a BCS Class II Drug, Rivaroxaban

• Main Authors: Daniel Zakowiecki (Author), Peter Edinger (Author), Markos Papaioannou (Author), Michael Wagner (Author), Tobias Hess (Author), Jadwiga Paszkowska (Author), Marcela Staniszewska (Author), Daria Myslitska (Author), Michal Smolenski (Author), Justyna Dobosz (Author), Grzegorz Garbacz (Author), Dorota Haznar Garbacz (Author)
• Format: Book
• Published: MDPI AG, 2024-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

<b>Background/Objectives</b>: The aim of the present study was to develop lactose-free formulations of rivaroxaban, a novel oral anticoagulant used for the treatment and prevention of blood clotting. As a BCS Class II drug, rivaroxaban is characterized by poor solubility in aqueous media...